Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors

Carcinogenesis

Volumn 22, Issue 1, 2001, Pages 17-25

  Richter, M ^a   Weiss, M ^a   Weinberger, I ^a   Furstenberger G ^b   Marian, B ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA; DRUG METABOLITE; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BAK; PROTEIN BCL 2; SC 58560; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ADENOMA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CLONE; COLON CARCINOMA; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME SPECIFICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

EID: 0035135598     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.1.17     Document Type: Article

References (34)

1. Cyclooxygenase, NSAIDs, and colorectal cancer
2. Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop
3. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
4. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
5. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis
6. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
7. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells
8. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
9. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
10. Inhibition of apoptosis during development of colorectal cancer
11. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac
12. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines
13. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat
14. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
15. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
16. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
17. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
18. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
19. Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms
20. Transforming growth factor βl acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation
21. Cell culture of human colon adenomas and carcinomas
22. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
23. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
24. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
25. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
26. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention
27. Sulindac inhibits activation of the NF-φB pathway
28. 2 production via a small GTPase, Rac1
29. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
30. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2 Mol
31. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma
32. COX-2 inhibitors. A new class of antiangiogenic agents
33. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
34. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: Regulation of COX-2 by butyrate